MEDICAL DIRECTOR

Position Overview

Sutro Biopharma, Inc. is seeking a driven and talented individual to join our Clinical Development team as we change the future of oncology. While collaborating with cross-functional departments, you will play a key leadership role in advancing our next-generation antibody-drug conjugate (ADC) portfolio. This individual will provide medical leadership across early clinical development programs, with a strong focus on Phase 1 and Phase 2 studies.

The Medical Director role is ideally suited for a physician-scientist with deep oncology expertise and prior experience in ADCs or targeted therapies. However, outstanding individuals with strong growth potential at an earlier stage of their career will also be considered. The appointee will work cross-functionally to translate Sutro’s differentiated, cell-free ADC platform, including single- and dual-payload technologies, into innovative clinical strategies aimed at improving efficacy, overcoming resistance, and expanding treatment options for patients with cancer. This position is an opportunity to be involved in translating industry-leading research and development from the laboratory into the clinic.

• Provide medical leadership for the design, execution, and interpretation of Phase 1/2 oncology clinical trials, with a focus on ADC programs
• Serve as medical monitor for assigned studies, ensuring patient safety, protocol compliance, and high-quality data
• Lead development of clinical protocols, investigator brochures, clinical study reports, and other key regulatory documents
• Contribute to and help shape overall clinical development strategy for ADC assets, including first-in-human studies and expansion cohorts
• Partner closely with translational sciences to integrate biomarker strategies, PK/PD insights, and mechanism-of-action data into clinical development plans
• Collaborate cross-functionally with clinical operations, regulatory affairs, CMC, nonclinical, and biometrics teams to ensure seamless program execution
• Engage and build strong relationships with key opinion leaders, investigators, and academic collaborators in oncology
• Support regulatory strategy and interactions, including preparation for FDA and global health authority meetings
• Analyze and interpret emerging clinical and translational data to inform dose selection, safety management, and program decisions
• Contribute to scientific publications, conference presentations, and external communications

• MD or MD/PhD required; board certification or eligibility in Oncology or Hematology/Oncology preferred
• Minimum of 2-5+ years of relevant experience with a minimum of 2 years of oncology clinical trial experience in pharmaceutical or biotech industries preferred
• Demonstrated experience leading or contributing to early-phase (Phase 1 and/or Phase 2) oncology clinical trials
• Prior experience with antibody-drug conjugates (ADCs) strongly preferred; experience with targeted therapies or biologics is a plus
• Solid understanding of oncology drug development, including clinical endpoints, dose escalation strategies, safety monitoring, and regulatory requirements
• Experience serving as a medical monitor on a registration study and interacting with regulatory agencies (e.g., FDA)
• Knowledgeable and current in GCP guidelines in US and Europe
• Strong scientific, analytical, and strategic thinking skills, with the ability to interpret complex clinical and translational data
• Proven ability to work effectively in a cross-functional, fast-paced biotech environment
• Up to 25% travel (US and international)

• Experience with novel payloads, linker technologies, or platform-based drug development approaches
• Familiarity with resistance mechanisms and combination strategies in oncology
• Clinical practice experience or experience as an investigator is a plus.
• Background in translational medicine and biomarker-driven development
• Track record of scientific publications and external presentations
• Ability to operate with agility and influence in a small, collaborative organization
• Excellent leadership, strategic thinking, and communication skills.
• Demonstrated commitment to high personal values and ethical standards.

Sound exciting? Apply today and join our team!

Sutro Biopharma, Inc. encourages all colleagues to be fully vaccinated for COVID-19 prior to the first date of employment.

As an equal opportunity employer, we believe in fostering a culture that is inclusive and values diversity in background and opinions. Sutro Biopharma hires extraordinary individuals into every position in the company and is committed to the diversity of our team. Our company progresses without regard of race, ethnicity, gender, sexual orientation, religious belief, age, disability or citizenship status. We are dedicated to creating a safe environment where our employees can grow and succeed together.

We look forward to hearing from candidates who are interested in exploring opportunities with Sutro! Our People & Culture team/hiring managers are unable to respond and do not accept solicitations from third-party agencies.

The anticipated salary range for fully qualified candidates applying for this role at Sutro Biopharma’s California based locations will be $245,000 - $300,000 (not including bonus, equity, and benefits). The final salary offered will be dependent on several factors that include and are not limited to relevant previous experience, job responsibilities and duration of experience, the type and length of experience within the industry and education.

About Sutro Biopharma

Sutro Biopharma, Inc. is advancing a next-generation antibody-drug conjugate (ADC) platform designed to deliver single- and dual-payload ADCs that enable meaningful breakthroughs for patients with cancer. By fully optimizing the antibody, linker, and payload, Sutro’s cell-free platform produces ADCs that are engineered to improve drug exposure, reduce side effects, and expand the range of treatable tumor types. With unique capabilities in dual-payload ADCs, Sutro aims to overcome treatment resistance and redefine what’s possible in cancer therapy. The Company’s pipeline of single- and dual-payload ADCs targets large oncology markets with limited treatment options and significant need for improved therapies.